[Place of hematopoietic stem cell transplantation for very high risk acute myeloblastic leukemia and myelodysplastic syndromes (SFGM-TC)].
Place de l’allogreffe dans les leucémies aiguës myéloblastiques et syndromes myélodysplasiques de très haut risque (SFGM-TC).
Allogreffe de cellules souches hématopoïétiques
Leucémie aiguë myéloblastique
Syndrome myélodysplasique
Very high-risk acute myeloid leukemia
Very high-risk myelodysplastic syndrome
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
05 Sep 2024
05 Sep 2024
Historique:
received:
18
04
2024
revised:
14
06
2024
accepted:
20
06
2024
medline:
7
9
2024
pubmed:
7
9
2024
entrez:
6
9
2024
Statut:
aheadofprint
Résumé
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, these transplants are complicated by a high rate of relapse in very high cytogenetic risk or refractory diseases. The benefit of this therapeutic strategy for these serious malignant hemopathies could therefore be reassessed. As part of the 14th workshop for the harmonization of allograft practices organized by the francophone society of bone marrow transplantation and cellular therapy (SFGM-TC) (SFGM-TC) in Lille in September 2023, the role of allograft for very high risk or refractory AML and MDS was challenged after analysis of published studies.
Identifiants
pubmed: 39242254
pii: S0007-4551(24)00276-5
doi: 10.1016/j.bulcan.2024.06.016
pii:
doi:
Types de publication
English Abstract
Journal Article
Practice Guideline
Langues
fre
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.